GALT logo

GALT Galectin Therapeutics Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.69
-0.12 (-4.27%)

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing…

Market Cap: $177.16Mgalectintherapeutics.com

Price

No data yet.

Social Signal Score

49
5d
53
2 mentions
—
30d
52
3 mentions
—
60d
46
4 mentions
—
90d
46
4 mentions
—
news: 4

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 2Sell 0Strong Sell 0
Avg price target$11+308.9%
Low $11Median $11High $11
Current Consensus

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.49
$-0.49–$-0.49
1 analysts
FY2026
$-0.26
$-0.26–$-0.26
1 analysts
FY2027
$-0.16
$-0.16–$-0.16
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Joel Lewis
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
0.38
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-51.85
galectintherapeutics.com